13 July 2012 - Ampio Pharmaceuticals Inc (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs, licensing distribution of these drugs and developing additional new drugs, has announced today the pricing of its previously announced underwritten public offering...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up